



NDA 21929/S-042

**SUPPLEMENT APPROVAL  
FULFILLMENT OF POSTMARKETING REQUIREMENT**

AstraZeneca Pharmaceuticals LP  
One MedImmune Way  
Gaithersburg, MD 20878

Attention: Angela C. Vickers  
Regulatory Affairs Director

Dear Ms. Vickers:

Please refer to your Supplemental New Drug Application (sNDA) dated February 28, 2017 and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Symbicort (budesonide and formoterol fumarate dihydrate) Metered Dose Inhaler, 80 mcg/4.5 mcg and 160 mcg/4.5 mcg.

This Prior Approval supplemental new drug application provides for changes to the prescribing information to incorporate the results of the required safety trial with Symbicort and revised class labeling for inhaled corticosteroid/long-acting beta agonist combination products, including removal of the Boxed Warning for asthma-related death. This supplement also provides for replacement of the Medication Guide with a Patient Information leaflet.

**APPROVAL & LABELING**

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**WAIVER OF HIGHLIGHTS SECTION**

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling text for the package insert, text for the patient information leaflet, and text for the instructions for use, with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **REQUIRED PEDIATRIC ASSESSMENTS**

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable.

Because none of these criteria apply to your application, you are exempt from this requirement.

### **FULFILLMENT OF POSTMARKETING REQUIREMENT**

We have received your submission dated May 10, 2016, containing the final report for the following postmarketing requirement listed in the April 14, 2011 postapproval postmarketing requirement letter.

- 1749-1 A randomized, double-blind, 26-week, active-controlled clinical trial comparing Symbicort (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol with budesonide HFA to evaluate the risk of serious asthma outcomes (hospitalizations, intubation, death) in 11,700 adult and adolescent patients 12 years of age and older with persistent asthma.

Final Protocol Submission: May 2011  
Trial Completion: February 2017  
Final Report Submission: June 2017

We have reviewed your submission and conclude that the above requirement was fulfilled.

This completes your postmarketing requirement acknowledged in our April 14, 2011, letter.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Carol F. Hill, Senior Regulatory Health Project Manager, at (301) 796-1226.

Sincerely,

*{See appended electronic signature page}*

Sally Seymour, MD  
Deputy Director for Safety  
Division of Pulmonary, Allergy, and Rheumatology Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

SALLY M SEYMOUR  
12/20/2017